# Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

> **NCT03551626** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 552 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT03551626
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-29
- **Primary completion:** 2020-10-05
- **Final completion:** 2021-09-16
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03551626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03551626, "Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT03551626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*